Skip to main content

COVID-19 to a COVID 111 - Avoiding Serious Outcomes

COVID-19 to a COVID 111 - Avoiding Serious Outcomes

Session Date:

Getting ahead of the game in managing drug-drug interactions with Dr Karl Cole, and post ICU impacts of critical illness with Dr Kylie Julian.

This session is facilitated by Dr Anna Brooks, Senior Lecturer teaching postgraduate virology, biotech and advanced cell characterisation technologies. Dr Brooks’ research is focused on immunoprofiling or advanced cell characterisation of various immune perturbations (infectious diseases, post-viral illnesses, vaccine and drug responses). Dr Brooks has over 15 years experience in human immunology, with specific training and expertise in advanced cell characterisation using high dimensional spectral flow cytometry.  Dr Brooks’ is currently leading a study to understand the underlying immune dysfunction of Long Covid and its relationship with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). In addition, she is a consultant and/or collaborator on a number of commercial projects, including clinical trials. 


With sponsorship from: